Group items tagged

We have world's best neurologist neurosurgeons doctors team in India, they provide specialist consulting, diagnostic treatment services. Book an online appointment at your nearest Apollo Hospital all over across in India.

Apollo Hospitals and clinics have dedicated team of best orthopedic doctors in India. They provide specialists consulting, diagnostic, other treatment and services.

Heart Clinic Surgeon - Meet our team of best cardiologist & cardiothoracic surgeons in India. We are providing specialists consulting, diagnostic treatment services in cardiology center at Apollo Hospitals

Apollo Hospitals has best team of urologist neurologist doctors and they provide best diagnostic & treatment services for various kidney & urological diseases

Meet our team of best transplant doctors and surgeons in India, providing specialist consulting, diagnostic & treatment services at Apollo Hospitals.

Meet our team of best bariatric doctors surgeons in India, providing specialist consulting, diagnostic & treatment services at Apollo Hospitals

Apollo Hospitals has best team of oncologist in India. We provide specialist consulting, diagnostic, treatment services, surgical, medical radiation.

Lifeline Laboratory is best path lab in Delhi NCR with NABL accreditation. We provide home collection service in Delhi NCR with accurate report within a day

If you are looking for health checkup done visit thier website and book youre test online

he global multiplex assays market is projected to reach USD 3.35 Billion in 2023 from USD 2.33 Billion in 2018, at CAGR of 7.5%. Multiplex assays enables the simultaneous detection of multiple analytes in a single run/cycle of the assay. The use of multiplex assays in companion diagnostics for increasing the safety & efficacy of therapies and the advantages of multiplex assays over conventional singleplex assays are driving the growth of the market.

Diagnostics developer MDNA Life Sciences has partnered with Aspire Pharma to introduce the new Mitomic Prostate Test (MPT) for clinical use in the UK.

Research and development (R&D) in liquid biopsy is increasingly being funded by both public and private sectors due to its promising features such as early detection of cancer tumour, new lesion characterisation and identification of cancer drug target.

Liquid biopsy, a minimally invasive cancer diagnostic tool, has gained momentum in the last five years due to its advantages over the archaic painful procedure of solid tumour biopsy.

City x-ray and Scan Clinic (P) Ltd is one of the best diagnostic center in Delhi, which offers best Ultrasound facilities. You can book a test and get the reports online.

Myocardial infarction or heart attack is a leading cause of death among individuals throughout the country. Awareness and knowledge about the remedial actions and the correct diagnosis are imperative to treat the patient. Dr.Rahul Gupta mentions the enemies… Read More »

When on TB treatment, people co-infected with #HIV and TB are three times more likely to die from #TB. To reduce these preventable and treatable HIV deaths from TB, you must have access to: Antiretroviral Therapy Regular TB screening TB diagnostics and treatment TB preventive therapy (if no TB symptoms) For More Info Visit Our Website: https://www.drpounders.com/ or Call Us: +1 214-520-8833

Britain's biotech firm Avacta Group on Monday (January 10) announced halting sales of its Covid-19 rapid antigen lateral flow test AffiDX to replace antibodies in the device and increase its ability to diagnose the Omicron variant. The company stated that AffiDX is capable of detecting Omicron when the virus is present in high numbers in samples, but the sensitivity of the test reduces at lower viral loads. The performance of all rapid antigen tests came under scanner in wake of a large number of mutations in the Omicron variant. AffiDX contains both a proprietary Affimer reagent and a commercially available antibody. The Affimer reagent detects the Omicron variant with the same sensitivity as the Delta variant, and performance of the antibody is paired with the Affimer reagent in the test. This has been affected by the additional Omicron mutations, the firm said. Alastair Smith, chief executive of Avacta Group, said: "Our determination to only provide high quality, high performance diagnostic tests has led us to the correct decision to pause all marketing of the AffiDX® lateral flow antigen test. We have, of course, been unable to market the product in the UK since October 2021, as the product continues to await approval under the new CTDA regulatory process.